Avastin Point/Counterpoint: Hamburg Responds To Genentech’s Arguments On Breast Cancer Claim
Executive Summary
In a point-by-point response, FDA Commissioner Hamburg rebuts Genentech’s many and varied arguments for maintaining bevacizumab’s accelerated approval in first-line metastatic breast cancer.